We need to translate Russian news post into natural English, format per rules.

First line: short headline under 90 chars, no markdown, no '#'.

Then blank line, then body split into short paragraphs (2-3 sentences each), separated by blank lines.

Wrap few genuinely important facts — key numbers, percentages, drug/company/gene names, dates — in double asterisks. At most 4-5 per post, never a whole sentence.

Wrap study/journal citations and publication references in single underscores (e.g. Nature Aging, July 2026).

We need to preserve facts, numbers, names, citations exactly. No added commentary.

We need to identify important facts: dates: 8 September (OpenAI published article), 166 pages, Lean formalization, 10,000 agents, 88 hours search, 17 hours verification, 1934 Jean Leray, 2000 Clay Mathematics Institute, etc. Also maybe "positive viscosity", "smooth external force", etc. But we need to be selective: at most 4-5 double asterisks.

We need to decide which facts are most important: maybe the date of publication, the 166-page length, the 10k agents, 88 hours, 17 hours verification, the 1934 Leray, 2000 Clay Institute. That's many. We need only 4-5.

We can choose: 8 September, 166 pages, ≈10,000 agents, 88 hours, 17 hours maybe that's 5. Or we could include the Clay Institute year 2000 as important. But we need to limit.

We need to wrap each fact individually with double asterisks, not whole sentences. So we can embed them within sentences.

We also need to wrap study/journal citations in single underscores. There's mention of a preprint by Levanta Alpöge and Tristan Buckmaster? Actually "В препринте Левента Альпёге и Тристана Бакмастера сингулярность строится для уравнения Эйлера, где вязкости нет." That's a citation but not a journal. Could treat as preprint by Levanta Alpöge and Tristan Buckmaster maybe. Also maybe we need to cite the article itself? Not needed.

We need to preserve the content exactly, just translate.

Let's draft translation.

Headline: something like "OpenAI claims proof of Navier–Stokes singularity with viscous fluid". Must be under 90 chars.

Let's count: "OpenAI claims proof of Navier–Stokes singularity with viscous fluid" length ~ 55. Good.

Now blank line.

Now body paragraphs.

Paragraph 1: OpenAI published article on September 8 with claimed proof of singularity in Navier–Stokes equations, released full 166-page text and Lean formalization. The Lean language automatically checks reasoning steps.

We need to embed double asterisks for key numbers: maybe September 8, 166 pages. Also maybe Lean is not a number, but it's a name; we might not need to asterisk. We'll keep numbers.

Paragraph 2: According to the claimed theorem, for any positive viscosity the authors prescribe a smooth external force acting in a limited region of space and time, yielding a smooth three‑dimensional flow with finite kinetic energy that becomes unboundedly fast in finite time. The flow starts from rest, forms a vortex around an axis where fluid spirals inward and moves along the axis; the vortex core radius shrinks faster than its height, so speed grows while the volume shrinks enough to keep energy finite.

We might include positive viscosity maybe not needed. Could include finite kinetic energy but that's descriptive.

Paragraph 3: To avoid a non‑smooth remainder at the core boundary, the authors add short‑wavelength velocity oscillations around the core; the background vortex shear amplifies these waves, and their average momentum transport cancels the remainder. Subsequent corrections and spatial localisation keep the external force smooth even as the maximum speed grows without bound.…

🔗 Read original →

Ovarian stiffness increases with age, linked to lower oocyte yield

A preprint published Preprint, September 8 measured ovarian tissue stiffness in 132 participants from fertility clinics. Researchers used shear‑wave elastography, an ultrasound technique that tracks tissue waves to gauge resistance to deformation. They compared the readings with ultrasound signs of tissue remodeling and with outcomes of IVF cycles.

In the first cohort, 16 women aged 33 or younger had an average stiffness of 13.3 kPa, while 16 women aged 37 or older averaged 18.8 kPa. With age, both the maximum value and the variability of the measurements increased. Mouse experiments from 2020 had suggested that old ovaries are about 2.5‑fold stiffer than young ones, and that collagenase can bring the tissue back toward youthful levels.

The age‑related rise in stiffness remained significant after adjusting for anti‑Müllerian hormone (AMH), a marker of follicular reserve, and for body‑mass index. A second cohort of 100 women aged 24‑45 showed the same three stiffness metrics climbing with age. These findings suggest that the ultrasonic measure reflects intrinsic tissue changes rather than hormonal or metabolic confounders.

To validate the ultrasound signal, researchers examined follicular fluid: the older group had lower levels of C6M, a fragment generated when collagen VI breaks down

🔗 Read original →

Zebrafish heart repair uses distinct cardiomyocyte layers for growth and regeneration

On September 8, biologists described in eLife a thin layer of cardiomyocytes in zebrafish hearts that helps assemble the muscle wall and coronary vessels during growth.

After injury, other cardiomyocytes rebuild lost tissue; zebrafish hearts can regenerate muscle after ventricular tip removal; surviving cardiomyocytes change state, divide, and replace the lost tissue; the heart consists of several such layers.

Researchers mapped 1,668 cardiomyocytes of adult heart and found a group with active phlda2 gene; these cells lie in a thin layer between outer compact muscle and inner trabeculae.

They created a fish line where phlda2-active cells produce bacterial NTR enzyme and become sensitive to metronidazole; treatment removed about 96.9% of these cells from the ventricle.

In young fish, trabecular muscle area became roughly 54.7% smaller, outer compact layer lost proper organization, and coronary vessels fragmented; after 90 days the vascular pattern remained disrupted.

This layer participates in how the growing heart assembles muscle and vascular network.

In adult fish, ventricular tip was removed six days after treatment start; one week later the wound contained as many gata4-active cells (a marker of dividing cardiomyocytes during repair) as in controls.

By day 30 new muscle covered the injury; vessel density and scar area matched controls; the phlda2‑active layer did not recover even after 60 days, and its cells did not overlap with those activating gata4 during regeneration, indicating that heart growth and adult tissue repair rely on different cardiomyocyte populations.

🔗 Read original →

BioPharma APAC Maps Four Longevity Funding Channels in Asia‑Pacific

On September 9, BioPharma APAC released a map of four channels of longevity financing in the Asia‑Pacific region. The map separates funds that pay for therapy development, diagnostics, clinic services, and scientific projects linked to the region but financed or incorporated outside it. Venture‑tracker records show when an investor receives equity after a deal.

Payments from pharmaceutical companies for joint development, research grants, and clinic revenue from examinations go to different recipients and support distinct work, which the author keeps separate. Therapeutic programs in the map draw venture money, public capital, grants, and pharma partnership payments. Biological‑age diagnostics — tests that assess age‑related changes in the body — form a separate line.

Two additional lines cover clinics and services funded

🔗 Read original →

Radical Numerics launches Omnii for personalized mRNA cancer vaccine target selection

On September 8, Radical Numerics unveiled Omnii, a post‑trained model designed to pick targets for personalized mRNA cancer vaccines. The system takes a tumor’s mutational profile and the patient’s MHC variants, then selects vaccine targets and builds an mRNA cassette sequence.

Omnii first predicts whether a mutant peptide will be presented by the patient’s MHC class I molecules on the tumor cell surface. It then estimates the peptide’s immunogenicity, i.e., whether a T‑cell will recognize the presented fragment and mount a response. Only peptides that pass both presentation and immunogenicity checks can be included in the vaccine cassette.

In head‑to‑head comparisons, Omnii achieved an AUROC 0.939 for MHC class I presentation, outperforming BigMHC‑EL’s 0.933. For immunogenicity prediction, the model scored AUROC 0.750, compared with 0.558 for BigMHC‑IM.

In a simulation where 100 candidate peptides were evaluated, only 6% were truly immunogenic and the cassette had five slots. Omnii selected an average of 1.3 immunogenic targets per cassette, while BigMHC‑IM managed just 0.7.

After target selection, Omnii outputs the mRNA sequence encoding the chosen neoantigens. The model is currently available in research preview, and Radical Numerics is seeking partners in cancer immunology and vaccine development.

🔗 Read original →

IRIS RNA model predicts developmental signals to improve stem cell differentiation

The IRIS model uses RNA profiles to infer which developmental signals acted on a cell. It was described in Nature Methods, September 8 after being trained on human stem cells exposed to known combinations of six developmental signals and then tested on single‑cell data from mouse embryos.

An RNA profile records which genes are currently active, giving a snapshot of the cell’s state. A benchmark of 400 models on cell atlases showed that merely expanding collections of RNA profiles quickly ceases to improve predictive power.

IRIS first learns from cells with known signal combinations, then searches the RNA profile for the trace of a signaling pathway—the chain through which a cell responds to an external cue. Researchers cultured human embryonic stem cells, applied defined signal mixes at different stages, and measured single‑cell RNA after each condition to teach IRIS to recognize these traces.

When applied to mouse embryo data, IRIS recovered the expected order of signal combinations in lineages that give rise to the foregut and heart muscle. It then predicted heightened activity of WNT and BMP in the prospective respiratory mesenchyme surrounding the lung bud.

In mouse foregut culture, activating WNT expanded the domain where the respiratory mesenchymal markers Tbx4 and Foxf1 are expressed, while a WNT inhibitor erased Tbx4 expression. Guided by this finding, the authors added WNT stimulation on the fourth day of differentiation of human stem cells and maintained it, which raised TBX4 levels and kept intermediate WNT activity to preserve FOXF1.

🔗 Read original →

OmniSyn builds 2.7‑billion‑entry virtual library for human protein drug design

A preprint describing OmniSyn was posted on bioRxiv, September 6. The computational model takes a protein’s amino‑acid sequence and proposes a candidate molecule together with a step‑by‑step synthesis plan that uses purchasable chemical fragments and reaction types. Unlike many structure‑based methods, OmniSyn relies solely on the sequence, selecting from over 220 000 fragments and 115 common reaction types during training.

The model was tested on 35 proteins not seen during training. For these targets OmniSyn identified exact matches to known active molecules in 0.255% of cases, compared with 0.028% for the next‑best method. When the candidates were analogues of known molecules, the retrosynthesis tool AiZynthFinder found a viable route for 71.92% of them.

For 21 306 human protein sequences OmniSyn generated 2.7 billion target‑molecule entries, each containing a synthetic route and scoring metrics for candidate selection. In a test on 200 proteins, the interaction score distinguished the true target from random proteins (7.64 vs 4.47) and the docking score showed better binding (−6.88 vs −6.20 kcal mol⁻¹).

The library stores, for every protein sequence, a virtual candidate, its synthesis plan

🔗 Read original →

Lipid nanoparticle with cerium oxide, CasRx plasmid, and D4F peptide reduces kidney injury

The authors described a lipid nanoparticle on 6 September that contains three parts: cerium oxide to scavenge reactive oxygen species, a plasmid expressing the CasRx protein guided by a short RNA to target STING transcripts, and the peptide D4F that directs the particle to kidney macrophages. In kidney organoids and a mouse model of transient blood‑flow occlusion, this construct lowered macrophage inflammation, tubular damage, and markers of kidney dysfunction.

Cerium oxide bound excess ROS, the plasmid drove CasRx production that cleaved STING RNA, and D4F facilitated particle accumulation in kidneys and binding to macrophages. In activated mouse macrophages the full construct decreased the proportion of cells showing a fluorescent ROS signal from 71.9% to 24.5%; a second guide RNA gave a similar reduction, while mutating the STING target site partially restored signal levels, confirming the effect depended on CasRx‑STING targeting.

Medium taken from macrophages treated with the nanoparticle reduced death, ROS signaling, and inflammatory gene activity in nearby tubular cells, even though the particles themselves did not reach the tubules, indicating that altered macrophage state can be transmitted via secreted factors. In kidney organoids, D4F increased the fraction of particles‑labeled cells from 9.65% to 27.5%.

In the mouse ischemia‑reperfusion model, two intravenous doses were given two hours before vessel occlusion and 30 minutes after blood flow returned; kidneys were evaluated after one day. Animals receiving the full construct showed the lowest tubular injury, creatinine, and blood urea nitrogen among all groups, with gene‑protein analysis revealing suppressed inflammatory pathways and enhanced oxidative‑stress defense and tissue‑repair programs.

🔗 Read original →

Stiff hydrogel boosts early bone formation via PIEZO1 mechanosensor in mice

In mouse experiments, a stiff water‑saturated hydrogel enhanced early bone formation through the mechanosensor PIEZO1. On 6 September, Advanced Science, September 6 published an article showing how a material placed in a bone defect alters cell behavior.

In normal mice with a 1‑mm femoral defect and hind‑limb unloading, a 15% GelMA hydrogel gave more new trabecular bone and collagen by day 7 than a 5% GelMA. This early time point involved five mice per group in the key comparisons.

Cells in the damaged bone contact the matrix, and the authors tested whether matrix stiffness steers cells toward bone or fat programs. Mouse mesenchymal stem cells cultured on gels with 2 and 25 kPa stiffness showed stronger osteogenic markers on the stiffer gel and more lipid droplets on the softer gel under adipogenic induction.

PIEZO1 is a membrane channel that admits calcium when deformed. Blocking mechanosensitive channels with GsMTx4 weakened the stiff‑gel effect, and deleting Piezo1 in mesenchymal progenitors abolished the bone‑program boost on stiff gel.

The authors traced the path from calcium to the gene Stc2, showing that CaMKII inhibition lowered active SP1 and STC2 levels; SP1 binds the Stc2 promoter to drive its transcription. Mutating the promoter reduced SP1 binding and reporter activity, supporting this link.

Even when PIEZO1 was pharmacologically inhibited, adding secreted STC2 shifted cells toward osteogenesis. In a separate experiment, a soft 5% GelMA supplemented with STC2 enhanced early bone‑formation signs in the defect.

In mice lacking Piezo1 in mesenchymal progenitors, neither soft nor stiff gels increased bone formation, and the difference between 5% and 15% GelMA disappeared; these controls were performed without hind‑limb unloading.

🔗 Read original →

Hakken model selects three biomedical hypotheses for lab testing

Hakken constructs a map of biomedical entities from publications, linking each pair with a relation type and the time it appeared in the literature. The model compares this structure to article fragments where the entities are mentioned separately and scores hypotheses that are absent from the authors’ working knowledge base. For each candidate it provides a short chain of known facts that explains the high score.

Experts focused on aging, taking 1,386 aging‑related genes; among 959,805 gene pairs Hakken identified 1,543,297 hypotheses above a set threshold. Known interactions were removed, and an automatic selection of the top three candidates per entity left 2,804 hypotheses for further consideration.

Biologists chose three hypotheses with model scores above 0.8 and sent them to an independent contract laboratory. In these experiments a “link” means functional regulation of gene expression: after a cellular intervention the level of messenger RNA (mRNA) or the corresponding protein changes.

For the TP53–BAMBI pair, the drug Nutlin‑3 raised the p53 protein encoded by TP53, and BAMBI mRNA increased by 16% after 24 hours and by 38% after 48 hours.

For the RAF1–TNF pair, the RAF1 inhibitor GW5074 produced a small, repeatable rise in TNF mRNA at 24 hours, while the amount of TNF secreted into the medium stayed below the detection limit.

The third hypothesis, SOAT1–STAT3, received no support: stimulating SOAT1 did not alter STAT3 mRNA or protein levels.

🔗 Read original →

Jim Greenwood urges longevity movement to partner with biotech groups to shape FDA policy

On September 9, Jim Greenwood told the Alliance for Longevity Initiatives (A4LI) that the longevity movement should work with biotech associations such as BIO and the Alliance for Regenerative Medicine to influence FDA rules. He proposed forming a political action committee (PAC) to repeatedly engage elected officials on a single issue and bringing family members of people with dementia and other age‑related diseases to congressional meetings.

Greenwood served 12 years in the U.S. House of Representatives. He was president and CEO of the Biotechnology Innovation Organization (BIO) from 2005–2020, a period during which BIO’s membership grew to more than >1,000 companies.

He identified the next reauthorization of the Prescription Drug User Fee Act (PDUFA) as a practical window for action, saying A4LI should formulate its requirements in advance and channel them through the associations that already sit at the FDA table. “A4LI will not be sitting at that table… it should work closely with those who are, because they can convey its demands to the FDA,” Greenwood said.

Greenwood tied this political strategy to the likely path of aging‑biology interventions, noting they will first demonstrate efficacy in individual age‑related diseases that already have an approval and reimbursement pathway. In his view, A4LI can simultaneously discuss future drug rules with Congress and the

🔗 Read original →

Nature reports chromosomal damage and mosaic editing in human embryos after base editor PCSK9 tweak

On Nature, September 9, 2026

On September 9, 2026, researchers published a study describing experiments on early human embryos targeting the PCSK9 and HBG genes with the adenine base editor ABE8e-V106W introduced at fertilization. The editor modified all PCSK9 alleles and permitted some embryos to reach the blastocyst stage, yielding embryonic stem cell lines with edited PCSK9.

The paper also notes a rare chromosome break at the target site, chromosomal abnormalities, and mosaic off‑target edits—different cells within the same embryo displayed distinct changes. While standard CRISPR/Cas9 creates double‑strand breaks that in early human embryos are associated with large deletions and loss of chromosomal segments, the adenine base editor produces a single‑strand nick and chemically alters a single DNA base.

PCSK9 and HBG were selected because they have been extensively studied in somatic cell editing, allowing the team to monitor how the embryo repairs such damage. After validating guide RNAs in cellular models, the editor was applied to human zygotes; delivering the editor protein together with its guide RNA enabled some embryos to develop to the blastocyst stage and produce PCSK9‑edited stem cell lines.

mRNA that encodes the editor frequently arrested development at early divisions, a effect the authors attribute to the deaminase activity of the editor independent of the guide RNA. A June 2026 review of the preprint had found no large deletions or chromosomal anomalies after editing, but the September article describes a different damage profile: a rare chromosome break at the target site, chromosomal anomalies, and mosaic off‑target edits near the targets and elsewhere in the genome.

When assessing safety, researchers examine the whole embryonic genome, chromosome status, and whether edits are uniform across cells. The authors conclude that the genomic and developmental consequences currently preclude clinical application of this approach in reproduction.

🔗 Read original →

Anthropic's Hubinger Says AI Extinction Risk Over 10% in Next Decade

On September 9, Evan Hubinger, head of AI alignment at Anthropic, replied to a thread by former colleague Jacob Cockson. He agreed with Cockson’s warning about a race toward self‑improving superintelligence and said Anthropic currently lacks a plan to align such a system with human interests.

The same day Jacob Cockson announced his departure from Anthropic. In his thread he described the situation as a race to self‑improving superintelligence, urged researchers to pursue alternative development conditions, and suggested a temporary halt on scaling model capabilities might be needed to avert a global race.

In his reply Hubinger added his personal assessment, stating that he believes the probability of AI causing human extinction in the next ten years is >10%. He said Anthropic is doing

🔗 Read original →

AI Agent Calibrates Six‑Qubit Chip, Improves Four of Forty Measurements

GPT‑5.6 Sol performed calibration of four qubits on a new MIT chip on September 8. Researchers intervened in only 4 of 40 target measurements to improve results. The agent, guided by OpenAI’s description of graduate student Beatrice Yankelevich’s work, used the Codex system to control measurements on a separate chip with six superconducting qubits.

Calibration sets the chip before experiments: the outcome of one measurement becomes the

🔗 Read original →

Philanthropists urged to fund low‑cost gerotherapy trials

On September 7, Fight Aging! published an essay by Reason explaining why testing a cheap therapy can cost far more than the therapy itself. He proposes that wealthy philanthropists fund early clinical programs to generate data. Gerotherapy targets biological aging processes and aims to reduce the risk of multiple age‑related diseases. The compound may be available in clinics, but its effect on aging must be established in a dedicated clinical trial.

In such a trial the participant group and the outcome to be measured—disease, physical function, or a combination—are defined in advance. For interventions that merely slow aging, Reason notes that observation must last at least five years to detect changes in age‑related disease incidence and mortality. He explains the difficulty with patent economics: a patent gives the developer exclusive sales rights and helps recoup R&D costs, whereas a cheap, easily copied therapy has weak patent protection; the trial can still be expensive, and investors have little incentive to pay because any supplier could benefit from the results.

“Interventions that could potentially be used against aging may remain on the market for decades without a sufficiently rigorous attempt to determine whether they actually treat aging and how well.” The essay also considers lowering medical‑regulation costs, medical tourism, and self‑experiment communities. According to the author, these routes broaden access to procedures, but reliable open data still require an organized clinical program. An article by an international geroscience working group explains why such a program needs time and money. Researchers first decide who to include in the trial and which treatment outcome to measure. Slow age‑related decline in physical function is only visible after long observation of large groups.

Scientists have not yet agreed on a universal biomarker—a measurable indicator in lab tests—that could signal aging. Therefore the price of the drug and the price of proof are separate quantities. Seeking early markers that could shorten the validation period is aided by the AFAR FAST program, which analyses samples from completed trials. Reason proposes that wealthy philanthropists fund the initial clinical programs for affordable candidates. In his model, philanthropists finance the trial data, which any supplier of the therapy could use.

🔗 Read original →

GPN-Star ranks DNA variants using cross‑species evolutionary constraints

GPN-Star compares a human DNA segment with the same segment across other species to estimate the evolutionary constraint of each single‑letter substitution. It builds a multiple‑sequence alignment of genomes and a phylogenetic tree that shows how closely related the species are. The model was described in Nature, September 9, 2026.

During training GPN-Star masks one DNA letter and predicts it from the surrounding human bases and the corresponding positions in other species, weighting closer relatives more heavily according to branch distances. The output is a probability for each possible base, from which an evolutionary‑constraint score is derived. Separate versions were trained on vertebrate, mammalian and primate alignments.

The vertebrate‑aligned version performed best at identifying substitutions in protein‑coding regions and rare high‑impact variants, whereas the mammalian and primate versions were stronger on regulatory regions that control gene expression. In practice the authors applied GPN‑Star to 34 quantitative traits from the UK Biobank, analysing 161,822 participants of European ancestry.

They added three GPN‑Star scores to the DeepRVAT statistical method, which searches for trait‑associated genes using rare variants. Across three runs the

🔗 Read original →

Blood cell reprogramming erases DNA methylation age marks

Researchers reprogrammed blood cells from 99 healthy donors into induced pluripotent stem cells (iPSCs) to test whether DNA methylation age signatures persist after reprogramming. They published their findings on 8 September.

Starting with peripheral blood mononuclear cells (PBMCs), they obtained 88 iPSC lines from donors aged 22–92 years after quality control. They retained 67 matched pairs of original blood and iPSC samples for direct methylation comparison.

In the original blood, epigenetic clocks showed higher methylation age with older donors, but in the iPSCs the age correlation disappeared across all five clock calculations. A genome‑wide analysis of all measured DNA sites, including those outside the clock sets, confirmed that age‑related signals were present in blood cells but absent in iPSCs.

The team also examined methQTL—statistical links between DNA variants and methylation levels—finding some shared between blood and iPSCs and some specific to each cell state, indicating that genetic influences on methylation differ after reprogramming. Consequently, to study blood‑specific methylation age patterns, the original blood sample is required because fully reprogrammed iPSCs carry a different methylation landscape.

🔗 Read original →

PromptBio releases preprint on PromptGenie system for biomedical computation tracking

On September 6, the PromptBio team posted a preprint on bioRxiv describing PromptGenie, a system for biomedical data research. The authors explain how it turns a research question into a plan, code, execution, and records that allow verification of the computational workflow. A biomedical question is transformed into output through a series of decisions: what data to use, which method to test a hypothesis, how to perform the calculation, and how to interpret results.

When these decisions reside in separate files, services, and email threads, it is hard to see from a final table or figure which data and choices led to it. In the preprint, the authors call PromptGenie a system that receives a research goal and available context, builds a plan of dependent steps, and adjusts subsequent steps based on intermediate results or errors. Before a major decision, the researcher can review and edit the plan.

The system then invokes a ready-made method or writes code, runs the calculation, and passes the result to the next step. Authors describe a journal where the plan and its modifications, data sources and references, parameters, execution environment details,

🔗 Read original →

Suppressing MEOX1 improves cardiac reprogramming after heart attack in mice

On September 8, researchers published in Circulation a study in which they treated mice after myocardial infarction with a cocktail of cardiac‑reprogramming factors together with a short RNA designed to suppress the MEOX1 gene.

Six weeks later, the mice that received MEOX1‑suppressing RNA had more cells expressing cardiac‑muscle markers, a smaller scar, and a markedly improved ejection fraction (38.1% versus 28.85% in the control group). The number of spontaneously contracting cells was also increased roughly about fourfold.

Further analysis showed that MEOX1 drives a scar‑promoting program and is upregulated by the profibrotic signal TGF‑β1; reducing its activity allowed fibroblasts to adopt a cardiomyocyte fate, whereas restoring MEOX1 or using a RNA‑resistant version abolished the benefit.

The same combination of reprogramming factors and MEOX1 inhibition also raised the proportion of cardiac‑muscle‑positive cells in cultured human fibroblasts, supporting the idea that blocking MEOX1 helps convert scar‑forming cells into functional heart muscle.

🔗 Read original →

FDA talks preventive therapies for multiple age-related diseases at H-SPAN summit

On September 9, the H‑SPAN longevity biotech summit hosted a panel on how the FDA should evaluate preventive therapies aimed at several age‑related diseases. The discussion built on questions raised in the July H‑SPAN summit report about which disease to target first and what metric to use to prove benefit.

Robert Kalesnik-Orshulak, who leads regulatory affairs at Retro Biosciences, argued that companies should start with a single indication, obtain early results, and then expand the label to other aging‑related conditions. He suggested using the FDA’s accelerated approval pathway, where a surrogate endpoint could serve as the basis for a decision.

David Fox, an FDA regulatory lawyer and co‑author of the Thrive Act, countered that testing a therapy meant to delay multiple chronic diseases before a serious diagnosis requires large cohorts, long follow‑up, and especially rigorous safety assessment. He noted that his Thrive Act outlines a staged evidence framework for prevention in people without a severe diagnosis.

Lowell Zeta, introduced as the FDA deputy commissioner for strategy and acting chief of staff, invited industry to submit data and proposals. He pointed to **Operation

🔗 Read original →

Experts propose labeling aging a 'metadisease' to streamline clinical trials

At the H-SPAN summit on 9 September, anatomist Antonney Chok urged that aging be described as a “metadisease” — a biological process that underlies several age‑related conditions. He argued that this framing would help clinical trials assess interventions targeting aging biology by measuring a set of related outcomes.

The discussion built on the July report of the H-SPAN summit, which devoted its second day to clinical endpoints and FDA regulations. Panelists asked what a single trial should test if a therapy alters the overall aging process, noting that endpoints must be predefined and measurable.

Chok explained that because aging drives multiple pathologies, an intervention will need a bundle of linked metrics rather than a single disease‑specific endpoint. He highlighted cellular senescence — the state in which cells cease dividing and alter tissue function — as a central mechanism in his model.

To enable one trial to evaluate several results, Chok proposed assigning an ICD code to aging as a metadisease. He also suggested creating a federal institute of gerontology alongside the National Institute on Aging to unite researchers who currently work in cancer, heart disease, or Alzheimer’s programs around shared aging biology.

🔗 Read original →